Issue of Equity

    RNS Number : 9971U
  Amarin Corporation Plc
  21 May 2008
   



    AMARIN MAKES APPLICATION FOR THE ADMISSION OF ORDINARY SHARES

    DUBLIN, Ireland, May 21, 2008 Amarin Corporation plc (NASDAQ: AMRN) (the "Company") has made an application to the London Stock Exchange
and the Irish Stock Exchange in respect of 869,565 ordinary shares of £0.50 each ("Ordinary Shares") in the capital of the Company to be
admitted to trading on AIM and IEX respectively.  The Ordinary Shares are to be issued in connection with Amarin's recently announced
private placement of equity.

    About Amarin
    Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous
system (CNS) diseases. Amarin's cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease,
epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of
molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation. Amarin has its primary
stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN").


    Contacts: 
    Amarin [phone] 
    Thomas Lynch, Chairman and Chief Executive Officer
    Alan Cooke, President and Chief Operating Officer
    Darren Cunningham, EVP Strategic Development and Investor Relations
    [e-mail] 

    Investors: 
    Lippert/Heilshorn & Associates, Inc. 
    Anne Marie Fields [phone]
    Bruce Voss [phone] 

    Media: 
    Powerscourt [phone] 
    Rory Godson 
    Paul Durman 

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
IOESEUFLFSASESI